AxioMx
Branford, Connecticut, United States
About AxioMx
AxioMx, founded in 2012 and based in Branford, Connecticut is a leader in recombinant antibody technologies. Its founders, Chris McLeod and Dr. Michael Weiner, are life science entrepreneurs who have previously led successful genomics, next-generation sequencing, microfluidics, bioinformatics and proteomic organizations. AxioMx’s unique platform of proprietary phage display libraries, library screening, and affinity maturation methods provides the technical foundation of the company. The company offers a full range of custom antibody discovery and development services for the research and diagnostic market places.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $4.5M
- Funding stage: M&A
- Last round: Series Unknown (Apr 2015)
- Website: axiomxinc.com
- Phone: 2034334068
Industries & Categories
Biotechnology, Health Diagnostics, Marketplace
Social Profiles
Canonical: https://fsome.com/organization/axiomx-2460778 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.